Nakano et al. developed a PIM3 inhibitor (Compound 11) using PIM1’s crystal structure as a surrogate to offer a foundation for rational drug design and showed that inhibition of PIM3 kinase activity reduced the proliferation of various pancreatic cancer cell lines. Here, PIM3 is linked to familial pancreatic carcinoma.